Aagam Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 22-12-2024
- Paid Up Capital ₹ 1.00 M
as on 22-12-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 22-12-2024
- Revenue 8.75%
(FY 2019)
- Profit 62.86%
(FY 2019)
- Ebitda 60.77%
(FY 2019)
- Net Worth 6.27%
(FY 2019)
- Total Assets -50.32%
(FY 2019)
About Aagam Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.00 M.
Ishan Shah, Hina Kothari, and Shaileshkumar Kothari serve as directors at the Company.
- CIN/LLPIN
U24100GJ2010PTC060331
- Company No.
060331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aagam Life Sciences Private Limited offer?
Aagam Life Sciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Pharma Franchise, Allopathic PCD Pharma Franchise, Diabetes Medicine, Sitagliptin Tablet, Common Disease Medicines, Injectable Products, Antihistamines, Arthritic Drugs.
Who are the key members and board of directors at Aagam Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ishan Shah  | Director | 20-Apr-2010 | Current |
| Hina Kothari | Director | 20-Apr-2010 | Current |
| Shaileshkumar Kothari | Director | 24-Jun-2016 | Current |
Financial Performance of Aagam Life Sciences.
Aagam Life Sciences Private Limited, for the financial year ended 2019, experienced modest growth in revenue, with a 8.75% increase. The company also saw a substantial improvement in profitability, with a 62.86% increase in profit. The company's net worth moved up by a moderate rise of 6.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aagam Life Sciences?
In 2019, Aagam Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Jul 2016 | ₹5.00 M | Open |
How Many Employees Work at Aagam Life Sciences?
Aagam Life Sciences has a workforce of 34 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aagam Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aagam Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
